{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:53:48Z","timestamp":1773906828788,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","pathologyjournal.rcpa.edu.au","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.pathol.2020.09.018","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:08:37Z","timestamp":1607119717000},"page":"462-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status"],"prefix":"10.1016","volume":"53","author":[{"given":"Eltjona","family":"Rrapaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Giacometti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-1410","authenticated-orcid":false,"given":"Paolo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido Alessandro","family":"Baselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Veggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"Rena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-3630","authenticated-orcid":false,"given":"Elena","family":"Trisolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo Luciano","family":"Boldorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2020.09.018_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.pathol.2020.09.018_bib2","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the north western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib3","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.21037\/jtd.2017.12.146","article-title":"Epidemiology of malignant mesothelioma in Italy: surveillance systems, territorial clusters and occupations involved","volume":"10","author":"Marinaccio","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.pathol.2020.09.018_bib4","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardothorac Surg"},{"issue":"18","key":"10.1016\/j.pathol.2020.09.018_bib5","first-page":"319","article-title":"Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health","volume":"110","author":"Neumann V,","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.pathol.2020.09.018_bib6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib8","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A\u00a0phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib9","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.pathol.2020.09.018_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pathol.2020.09.018_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00101008","article-title":"Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells","volume":"34","author":"Jackaman","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pathol.2020.09.018_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"Suppl 5","key":"10.1016\/j.pathol.2020.09.018_bib14","first-page":"v851","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib15","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.pathol.2020.09.018_bib17","article-title":"A\u00a0study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib20","author":"NIH: ClinicalTrials.gov"},{"key":"10.1016\/j.pathol.2020.09.018_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pathol.2020.09.018_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pathol.2020.09.018_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2020.09.018_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.pathol.2020.09.018_bib26","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2020.09.018_bib28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib31","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Canc"},{"key":"10.1016\/j.pathol.2020.09.018_bib32","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib33","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib34","first-page":"14595","article-title":"Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib35","first-page":"5369","article-title":"Programmed Death-1 Ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II\/III gastric cancer","volume":"35","author":"Tamura","year":"2015","journal-title":"Anticanc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Canc Ther"},{"key":"10.1016\/j.pathol.2020.09.018_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib42","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","first-page":"1240","author":"Travis","year":"2015"},{"key":"10.1016\/j.pathol.2020.09.018_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017. Update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2020.09.018_bib44","series-title":"TNM Classification of Malignant Tumours","year":"2017"},{"key":"10.1016\/j.pathol.2020.09.018_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of different antibody clones for immunohistochemistry detection of Programmed Cell Death Ligand 1 (PD-L1) on non-small cell lung carcinoma","volume":"26","author":"Parra","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.pathol.2020.09.018_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.pathol.2020.09.018_bib47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib48","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib49","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2020.09.018_bib50","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2020.09.018_bib51","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Canc Res"},{"issue":"2","key":"10.1016\/j.pathol.2020.09.018_bib52","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2020.09.018_bib53","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat Immunol"},{"issue":"24","key":"10.1016\/j.pathol.2020.09.018_bib54","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2020.09.018_bib55","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2020.09.018_bib56","first-page":"37","article-title":"Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study","volume":"12","author":"Wang","year":"2019","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.pathol.2020.09.018_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12935-019-0955-2","article-title":"PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer","volume":"19","author":"Jiang","year":"2019","journal-title":"Canc Cell Int"},{"issue":"Suppl","key":"10.1016\/j.pathol.2020.09.018_bib58","article-title":"Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression","volume":"35","author":"Rivalland","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2020.09.018_bib59","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2020.09.018_bib60","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/ijms18122540","article-title":"The roles of microRNAs in regulating the expression of PD-1\/PD-L1 immune checkpoint","volume":"18","author":"Wang","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2020.09.018_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252030965X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252030965X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T17:24:27Z","timestamp":1639848267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130252030965X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S003130252030965X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2020.09.018","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2020.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}